As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Design Therapeutics, Inc. The largest reported stake is SR One Capital Fund I Aggregator, LP's, at 10.7%. 9 filings are on record since August 28, 2025 (Schedule 13D/A, March 11, 2026).
Sell to companies like Design Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 5,963,936 · Sole dispositive: 0 · Shared dispositive: 5,963,936 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 2,366,453 · Sole dispositive: 0 · Shared dispositive: 2,366,453 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Point72 Asset Management, L.P. · Percent: 5.1% · SCHEDULE 13G
- · Holder: Point72 Asset Management, L.P. · Percent: 4.4% · SCHEDULE 13G/A
- · Holder: SR One Capital Fund I Aggregator, LP · Percent: 10.7% · SCHEDULE 13D/A
Design Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-28. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| SR One Capital Fund I Aggregator, LP | 10.7% | 6,526,476 | SCHEDULE 13D/A, 2026-03-11 | 2026-03-09 |
| Sirenia Capital Management LP | 9.5% | 5,963,936 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Logos Global Management LP | 4.4% | 2,500,000 | SCHEDULE 13D/A, 2025-11-18 | 2025-11-14 |
| Point72 Asset Management, L.P. | 3.8% | 2,366,453 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Design Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Design Therapeutics, Inc. and the records around it.
Design Therapeutics, Inc. elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Watch Design Therapeutics, Inc.
Get an email when Design Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Design Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Design Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Design Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Sirenia Capital Management LP | 0 | 5,963,936 | 0 | 5,963,936 | SCHEDULE 13G, 2026-08-14 |
| Alex Silverstein | 0 | 5,963,936 | 0 | 5,963,936 | SCHEDULE 13G, 2026-08-14 |
| Point72 Asset Management, L.P. | 0 | 2,366,453 | 0 | 2,366,453 | SCHEDULE 13G/A, 2026-08-14 |
| Point72 Capital Advisors, Inc. | 0 | 2,366,453 | 0 | 2,366,453 | SCHEDULE 13G/A, 2026-08-14 |
| Steven A. Cohen | 0 | 2,366,453 | 0 | 2,366,453 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Design Therapeutics, Inc. by CUSIP 25056L103 and gives its principal executive office as 6005 Hidden Valley Road, Suite 110, Carlsbad, CA 92011 (SCHEDULE 13G, 2026-08-14).
Purpose of Transaction (Item 4)
Logos Global Management LP
The reporting persons filed this Schedule 13D because Dr. William was on the Issuer' board of directors. Dr. William resigned from the Issuer's board of directors on September 9, 2025. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional securities in the open market, through privately negotiated transactions with third parties or otherwise, and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the securities now owned or hereafter acquired by any of them. The reporting persons also may from time to time enter into or unwind hedging or other derivative transactions with respect to the Stock or pledge their interests in the Stock to obtain liquidity. In addition, from time to time the reporting …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-18; the filing has the rest
SR One Capital Fund I Aggregator, LP
Not applicable.Item 4 of the SCHEDULE 13D/A filed 2026-03-11
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-28 | Point72 Asset Management, L.P. | 5.2% | SCHEDULE 13G |
| 2025-11-12 | Logos Global Management LP | 5.7% | SCHEDULE 13D/A |
| 2025-11-18 | Logos Global Management LP | 4.4% | SCHEDULE 13D/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 9.4% | SCHEDULE 13G/A |
| 2026-03-11 | SR One Capital Fund I Aggregator, LP | 10.7% | SCHEDULE 13D/A |
| 2026-05-15 | Point72 Asset Management, L.P. | 4.4% | SCHEDULE 13G/A |
| 2026-06-09 | Point72 Asset Management, L.P. | 5.1% | SCHEDULE 13G |
| 2026-08-14 | Sirenia Capital Management LP | 9.5% | SCHEDULE 13G |
| 2026-08-14 | Point72 Asset Management, L.P. | 3.8% | SCHEDULE 13G/A |
Questions about who owns Design Therapeutics, Inc.
Who owns Design Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Design Therapeutics, Inc.: SR One Capital Fund I Aggregator, LP (10.7%, Schedule 13D/A, filed 2026-03-11) and Sirenia Capital Management LP (9.5%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Design Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Design Therapeutics, Inc. on this page are SR One Capital Fund I Aggregator, LP (10.7%) and Sirenia Capital Management LP (9.5%).
When did SR One Capital Fund I Aggregator, LP buy into Design Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from SR One Capital Fund I Aggregator, LP on this page is the Schedule 13D/A, filed 2026-03-11, reporting 10.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Design Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 1, 2026 | Leadership change: David Shapiro appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Design Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.